A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections-authors' response

J Antimicrob Chemother. 2022 Oct 28;77(11):3210-3211. doi: 10.1093/jac/dkac282.

Authors

Xu Zhao^{1

2}, Haihui Huang^{1

2}, Hong Yuan³, Zhengyu Yuan³, Yingyuan Zhang^{1

2}

Affiliations

¹ Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
² Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.
³ Shanghai MicuRx Pharmaceutical Co., Ltd., Shanghai, China.

PMID: 35972415
DOI: 10.1093/jac/dkac282

No abstract available

Publication types

Randomized Controlled Trial
Multicenter Study
Comment

MeSH terms

Adult
Anti-Bacterial Agents / adverse effects
Double-Blind Method
Humans
Linezolid / adverse effects
Oxazolidinones*
Pyridones
Skin Diseases, Bacterial* / drug therapy
Soft Tissue Infections* / drug therapy
Treatment Outcome

Substances

Linezolid
contezolid
Oxazolidinones
Pyridones
Anti-Bacterial Agents